1. Home
  2. MP vs SYRE Comparison

MP vs SYRE Comparison

Compare MP & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MP Materials Corp.

MP

MP Materials Corp.

HOLD

Current Price

$59.39

Market Cap

7.4B

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$103.29

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MP
SYRE
Founded
2017
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
8.5B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
MP
SYRE
Price
$59.39
$103.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
12
Target Price
$75.25
$85.08
AVG Volume (30 Days)
6.9M
807.9K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
12.28
N/A
EPS
N/A
N/A
Revenue
$331,952,000.00
N/A
Revenue This Year
$100.51
N/A
Revenue Next Year
$60.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.15
N/A
52 Week Low
$37.81
$14.51
52 Week High
$100.25
$108.14

Technical Indicators

Market Signals
Indicator
MP
SYRE
Relative Strength Index (RSI) 67.78 56.06
Support Level $51.86 $92.37
Resistance Level $64.62 $105.09
Average True Range (ATR) 3.09 5.82
MACD 1.99 -0.40
Stochastic Oscillator 91.33 69.63

Price Performance

Historical Comparison
MP
SYRE

About MP MP Materials Corp.

MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: